Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Capsules Relative to That From Co-administration of ABT-335 and Rosuvastatin for the 5/45mg Dosage Form.

Completed · Phase 1

Conditions studied: Adverse Events, Pharmacokinetic Variables

In brief

The purpose of this study is to compare the pharmacokinetics of ABT-335 and rosuvastatin from ABT-143 relative to that from the co-administration of ABT-335 and rosuvastatin.

Key facts

Study ID

NCT00728780

Run by

AstraZeneca

People needed

32

Starts

2008-08-01

Last updated by the study team

2012-09-28

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Signed informed consent
• Condition of good health

You may not qualify if…

• Currently enrolled in another study
• Females who are pregnant or breast feeding

Where it is running

• Site Reference ID/Investigator# 11101 — Evansville, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.